PITTSBURGH, Feb. 25 /PRNewswire/ -- Precision Therapeutics announced today that The National Comprehensive Cancer Network(R) (NCCN(R)) recently updated the NCCN Clinical Practice Guidelines for Oncology (NCCN Guidelines(TM)) for Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer to include the use of chemosensitivity/resistance assays as part of the Principles of Chemotherapy section. While the NCCN Guidelines(TM) state that this technology is not intended to supplant standard of care chemotherapy, chemosensitivity/resistance assays are being used in some NCCN Member Institutions for decisions related to future chemotherapy in situations where there are multiple equivalent chemotherapy options available. This is a NCCN category 3 recommendation.
"We offer our gratitude to NCCN on behalf of the many ovarian cancer patients who could be faced with the potential side effects of ineffective chemotherapies. Not only are oncologists recognizing the benefits of using chemosensitivity and resistance assays when faced with equivalent therapeutic options, but they are also paving the way for greater support of personalized medicine in oncology," says Karen Kaplan, CEO of the Ovarian Cancer National Alliance.
The NCCN Clinical Practice Guidelines in Oncology(TM) are developed and updated through an evidence-based process with explicit review of the scientific evidence integrated with expert judgment by multidisciplinary panels of physicians from NCCN Member Institutions. The most recent version of this and all the NCCN Guidelines(TM) are available free of charge at NCCN.org.
About Precision Therapeutics
Precision Therapeutics, headquartered in Pittsburgh, Pennsylvania, is a life science company and leader in the development of innovative technology that delivers personalized diagnostics to physicians with the goal of supporting and optimizing difficult treatment decisions in cancer therapy.
For more information:
http://www.precisiontherapeutics.com
http://www.chemofx.com
CONTACT: Pam Ranallo of Precision Therapeutics Inc., +1-412-432-1500, ext.
1502, pranallo@ptilabs.com
Web site: http://www.precisiontherapeutics.com/
